why does nobody talk about API source
Something I noticed reading old threads that I have not seen said out loud.
The advice on 503B in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
shortage list status is API source, check the actual list
503B compounding is different from 503A, different rules, different legality
Yeah, 503A and 503B are different regulatory animals.
the 503A/503B distinction is load-bearing, do not blur it
API transparency is the question that separates good compounders from sketchy ones
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
Retitled to remove editorialising. Put the evidence in the body.
What is the actual shortage list status right now?
Mechanistically the bit that matters is 503B. It explains most of the early profile and a decent chunk of the outcome.
no pharmacy referral codes, naming is fine, recruiting is not
Strongly agree. API source transparency matters.
Did they tell you their API source or dodge the question?
no pharmacy referral codes, naming is fine, recruiting is not
no pharmacy referral codes, naming is fine, recruiting is not
Adding to this: 503B is doing more work than the comment implies.
the shortage list is temporary, it ends and compounding becomes illegal again
Are we talking 503A or 503B?
telehealth prescriber models exist, pricing differs by state
Small correction: the trial was 10 weeks, not 25. Does not change your point but people will quote it.
the Poland situation is different from the US, different regulations
Disagree. What you are describing is consistent with telehealth, not with what you concluded.
Slight fix: the number was 97.6, not 99.3. Decimal point, but a fairly consequential one.
Slight fix: the number was 97.6, not 99.3.
Disagree on that part. 99.2% and 98.9% on the same vial is normal.
What is the actual shortage list status right now?
the the UK situation is different from the US, different regulations
telehealth costs shortage list plus compounding markup, total varies
This is correct. The shortage list does expire and the rules change.
Which state? Rules vary.
This is correct. The shortage list does expire and the rules change.
the shortage list is temporary, it ends and compounding becomes illegal again
- 1Mechanistically the bit that matters is 503B. It explains most of the early…11 comments in this branch · started by u/camila_sandvik
- 2Disagree. What you are describing is consistent with telehealth, not with…7 comments in this branch · started by u/slow_logbook